Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal AST-726 for migraine prophylaxis
2005-003349-15Phase 2Completed
- Sponsor
- Ariston Pharmaceuticals, Inc.
- Start
- Nov 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AST-726 in migraine, migraine with aura and migraine without aura (3 arms), sponsored by Ariston Pharmaceuticals, Inc. Primary endpoint: Change in headache days per month relative to baseline. Started Nov 2005; status: completed.
02
Drugs
AST-726
03
Conditions
migrainemigraine with auramigraine without aura
Beyond the preview
Go deeper on 2005-003349-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003349-15.